08/23/2011

Research Poster - Assay Standardization Saves Money

Tags: , , , , ,

The identification and application of correlates of immune response can enable significant time and money savings especially in clinical trial settings for vaccine and biologic R&D. To download, please fill in the form below: Share this:

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


07/29/2011

Case Study – Develop Stronger, Longer Lasting Protective Coatings

Tags: , , , , ,

How Particle Testing Analysis Helps Praxair Surface Technologies Make Stronger, Longer Lasting Protective Coatings For Diverse Products Leading global supplier of surface-enhancing processes and materials counts on ImmunoSite Technologies particle testing services to ensure the highest quality for coatings that protect and endure in harsh environments. To download, please fill in the form below: Share […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


04/25/2011

Stepping Stones to Success with Drug Treatments for Melanoma

Tags: , , ,

Recently, it was announced that the Food and Drug Administration has approved a breakthrough cancer medication from Bristol-Myers Squibb Co. that researchers have heralded as the first drug shown to prolong the lives of patients with advanced skin cancer.  Share this:

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


04/03/2011

ImmunoSite Technologies Provides Particle Testing Services to Beckman Coulter Customers

Tags: , , , , , , , ,

IST employs a wide range of particle testing technologies

Leading provider of particle testing services now receives referrals of customers seeking particle characterization services from Beckman Coulter, Inc. Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


03/11/2011

The Need for New Surrogate Markers for Immune Monitoring and Efficacy Assessment

Tags: , , , ,

Current Paradigm Needs Change

It is of concern of all in pharma and biotech research fields that the number of vaccines and drugs that get to the market is very low compared to the number that enter phase I clinical trial testing. For this to change, among other improvements, new surrogate markers must be identified early on for the purpose of patient stratification, immune monitoring and/or therapeutic or prophylactic efficacy assessment.

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


03/10/2011

How Useful are Cell Mediated Immunity Assays in Assessing Immune Response or Immunogenicity?

Tags: , , , ,

If, Then

How practical is it to run validated and standardized cellular assays to interrogate biomarker surrogate correlates of immunity in clinical trial settings? Can this be done with any level of confidence in the outcome? Can these assays be performed routinely? Share this:

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


01/19/2011

BioFlorida Event-Newest Trends in Clinical Drug Development

Tags: , , ,

Tuesday, March 29, 2011 – Please join in with the topical discussions about the newest trends in clinical drug development, and learn strategies to avoid costly mistakes and improve efficiency.  The focus of this BioFlorida SE Chapter-sponsored event is on advancing biomedical products through the clinical development process, and is being led by Planning Committee […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


01/11/2011

Special Phacilitate Session on Cell Mediated Immunity

Tags: ,

Dr. Wade E. Bolton, president & CEO of ImmunoSite Technologies, moderated a special session on Cell Mediated Immunity (CMI) at the Phacilitate Vaccine Forum in Washington, DC, on Tuesday, January 25, 2011. Topics included: Do you want standardized assays to interrogate surrogate correlates of immunity? Do you need high-throughput, validated, and automated assays to measure immunogenicity? […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


01/10/2011

Validation of Cell-Based Assays in the GLP Setting

Tags: , , , , , ,

Readers gain an understanding of the details and the high level considerations of assay qualification for difficult cell-based assays. The level of optimization described for cell-based assays lends itself to biomarker assay automation which can be used for biomarker qualification and validation studies to the satisfaction of the FDA, EMEA, and other regulatory agencies.
Cell-based assay platforms covered are flow cytometry, intracellular cytokine ICS, immunophenotyping, elispot, IHC, cylex, neutralization bioassays, and endpoint assays.

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading